JP1520 PIK3CA E545K HA
(Plasmid
#14571)
-
Depositing Lab
-
Publication
-
Sequence Information
Full plasmid sequence is not available for this item.
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 14571 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneJP1520
-
Backbone manufacturerJeff Engelman
-
Vector typeMammalian Expression, Retroviral
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert namePIK3CA E545K
-
Alt namePIK3CA
-
Alt namep110 alpha
-
SpeciesB. taurus (bovine)
-
MutationE545K
-
Entrez GenePIK3CA
-
Tag
/ Fusion Protein
- HA tag (C terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ sequencing primer n/a (Common Sequencing Primers)
Resource Information
-
Articles Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Hemagglutinin (HA)–tagged bovine PIK3CA cDNA was subcloned into the pDNR-Dual vector (Clontech, Mountain View, CA), and site-directed mutagenesis (Quick Change, Stratagene, La Jolla, CA) was used to generate the E545K mutation. The cDNA was shuttled into the JP1520 retroviral vector using the BD Creator System (Clontech).
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
JP1520 PIK3CA E545K HA was a gift from Joan Brugge (Addgene plasmid # 14571 ; http://n2t.net/addgene:14571 ; RRID:Addgene_14571) -
For your References section:
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS. Cancer Res. 2005 Dec 1. 65(23):10992-1000. 10.1158/0008-5472.CAN-05-2612 PubMed 16322248